Sign in
CompletedNo phase

Clinical Study of UC-MSC Combined With Immunosuppressive Agents in the Treatment of Pediatric HAAA

Key facts

Who runs it
Institute of Hematology & Blood Diseases Hospital, China
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
20 people enrolled
Started
1 Sept 2021
Ended
31 Oct 2025
Type of study
Interventional
Treatments tested
  • UC-MSC
Record updated
30 September 2026

Who can take part

Age
1 year to 18 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • 1 Age < 18 years old, gender is not limited; 2 Diagnosis of hepatitis related aplastic anemia according to the criteria for hepatitis related aplastic anemia
  • The patient has a history of acute prehepatitis, and the course of hepatitis is generally less than 6 months. The main clinical manifestations are fever, jaundice, anemia, bleeding, generally no liver enlargement
  • Routine blood test: pancytopenia, HGB < 100 g/L; Absolute neutrophil count < 1.5×109/L; PLT < 100×109/L (PLT reduction must be included in case of two-series reduction). Serum aminotransferase levels were elevated at least 200 U/L and hepatitis autoantibodies were negative
  • Bone marrow aspiration and biopsy confirmed aplastic anemia
  • Jaundice caused by other reasons and other pancytopenia diseases (such as congenital AA, clonal diseases and autoimmune diseases, etc.) are excluded; 3 No hematopoietic stem cell transplantation (HSCT); 4 The guardian and the subject will participate voluntarily and sign the informed consent

Who cannot take part

  • 1 Patients will not be enrolled in this study if they meet any of the following conditions: 2. Patients with a history of hematopoietic stem cell transplantation; HIV infection or carrier in the past or at the time of screening; Positive for syphilis; 4. The subject had developed malignant solid tumors of any organ system within 5 years prior to screening; 5. Participated in other clinical trials within 3 months

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this clinical trial is to evaluate the effectiveness of umbilical cord mesenchymal stem cells combined with standard immunosuppressive therapy in children with HAAA, and to provide a new therapeutic idea for children with HAAA.

Read full original descriptionShow less

Whether UC-MSC combined with immunosuppressants can improve outcomes in children with HAAA.

Whether UC-MSC is safe in the treatment of children with HAAA.

Participants will:

1 Age < 18 years old, gender is not limited; 2 Diagnosis of hepatitis related aplastic anemia according to the criteria for hepatitis related aplastic anemia;

1. The patient has a history of acute prehepatitis, and the course of hepatitis is generally less than 6 months. The main clinical manifestations are fever, jaundice, anemia, bleeding, generally no liver enlargement. 2. Routine blood test: pancytopenia, HGB < 100 g/L; Absolute neutrophil count < 1.5×109/L; PLT < 100×109/L (PLT reduction must be included in case of two-series reduction). Serum aminotransferase levels were elevated at least 200 U/L and hepatitis autoantibodies were negative. 3. Bone marrow aspiration and biopsy confirmed aplastic anemia. 4. Jaundice caused by other reasons and other pancytopenia diseases (such as congenital AA, clonal diseases and autoimmune diseases, etc.) are excluded.

3 No hematopoietic stem cell transplantation (HSCT); 4 The guardian and the subject will participate voluntarily and sign the informed consent;

The group in the trial

  • UC-MSC + IST groupTreatment being tested

    UC-MSC Combined With Immunosuppressive Agents in the Treatment of Pediatric HAAA

    Treatment: UC-MSC

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Clinical Study of Umbilical Cord Mesenchymal Stem Cells Combined With Immunosuppressive Agents in the Treatment of Children With Hepatitis Associated Aplastic Anemia
Record updated
30 September 2026